Lorigerlimab

洛瑞格利单抗

Report date: 2026/05/23 20:00:57

Base Information

Drug NameLorigerlimab
Drug Alias NamePD-1 x CTLA-4 Tetravalent Bispecific DART® Protein(Macrogenics)EXPASYMGD-019AEX1344
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1Cytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSkin MelanomaOvarian Clear Cell CarcinomaHormone-Resistant Prostate Neoplasms +[23] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaCanada +[13] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMacrogenics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMacrogenics Inc
Inactive CompaniesThe University Of Texas MD Anderson Cancer CenterBayer AG
Active IndicationsSkin MelanomaOvarian Clear Cell CarcinomaHormone-Resistant Prostate Neoplasms +[19] 
Inactive IndicationsNeoplasm MetastasisUterine Cervical NeoplasmsRectal Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A